eResearchTechnology and Inveresk Sign Agreement to Deliver Integrated Cardiac Safety and Clinical Pharmacology Services
April 07 2004 - 9:02AM
PR Newswire (US)
eResearchTechnology and Inveresk Sign Agreement to Deliver
Integrated Cardiac Safety and Clinical Pharmacology Services Fifth
Clinical Research Organization Enters into Digital Cardiac Safety
Monitoring Services Agreement with eResearchTechnology
PHILADELPHIA, April 7 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, today announced it has entered into an
agreement with Inveresk, one of the world's largest clinical
research organizations. This alliance, the fifth for eRT, enables
testing of new drug candidates in conjunction with emerging
international cardiac safety regulatory guidance and technical
standards. Under the agreement, Inveresk will conduct clinical
trials at its Phase I unit in Edinburgh, Scotland, while eRT will
perform digital collection, measurement, interpretation, review and
distribution of cardiac safety data through its EXPeRT
workflow-enabled data handling technology. The eRT technology is
the first solution designed explicitly to meet emerging
international guidance and standards related to cardiac safety
monitoring services. "Inveresk's long operating history of
providing comprehensive Phase I unit services for over fifteen
years presented a great opportunity for eRT to extend its Thorough
Phase I ECG Study partnership program to Europe," said Robert
Brown, senior vice president of outsourcing partnerships for eRT.
"The partnershipwill help to meet increasing demand from European
and North American drug development organizations for the ability
to conduct Thorough Phase I ECG studies in Europe. We are pleased
to be announcing the Inveresk alliance and look forward to working
closely with the Inveresk team to ensure effective execution of
Thorough Phase I ECG studies." Based in Philadelphia, Pa.,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand and the company's
ability to obtain new contracts and accurately estimate net
revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles